Ansun BioPharma Publishes Effects of FluDase™ on Drug Resistant Flu

Jul 07, 2015, 06:00 ET from Ansun BioPharma

SAN DIEGO, July 7, 2015 /PRNewswire/ -- Ansun Biopharma announced today the publication of the report "Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181 (FluDase), a host-directed antiviral" in the peer the reviewed Journal "Antiviral Research." The report describes a case of an ill cystic fibrosis patient who was first treated with Tamilfu and then with IV Relenza but continued to deteriorate clinically and shed influenza virus. The virus was tested by the CDC and had been shown to be resistant to Tamiflu. Under an emergency use IND, the patient was then treated with FluDase and clearance of the virus was achieved.  

"This case exemplifies the potential clinical utility of FluDase, as a host directed antiviral, with the ability to have clinical activity against resistant strains," noted Dr. Ronald Moss CEO of Ansun BioPharma.  "In 2008-2009, close to 100% of H1N1 influenza A virus in the U.S. was resistant to Tamiflu," noted Dr. Moss. "With continued concerns regarding an influenza pandemic, we believe that FluDase, an investigational antiviral, remains an important countermeasure, particularly in sick hospitalized patients."

The article can be found on line at: http://www.intmedpress.com/journals/avt/abstract.cfm?id=2977&pid=48

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  Ansun BioPharma has two products in late stage clinical development. FluDase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDase is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDase has received Fast Track Designation by the U.S. FDA. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

 

SOURCE Ansun BioPharma



RELATED LINKS

http://www.ansunbiopharma.com